Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dalteparin sodium - Pfizer

Drug Profile

Dalteparin sodium - Pfizer

Alternative Names: Boxol; FR 860; Fragmin; Fragmine; KABI 2165; KV 2165; Tedelparin; Tedelparine

Latest Information Update: 03 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antithrombotics; Low molecular weight heparins
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes; Deep vein thrombosis; Thromboembolism
  • Registered Venous thromboembolism

Most Recent Events

  • 13 Jun 2019 Safety data from a phase II trial in presented at the 24th Congress of the European Haematology Association (EHA-2019)
  • 16 May 2019 Preregistration for Venous thromboembolism (In adolescents, In children, In infants) in USA (SC) prior to May 2019
  • 16 May 2019 Registered for Venous thromboembolism (In adolescents, In children, In infants) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top